lsd1/hdac6 in 1

LSD1/HDAC6-IN-2 (JBI-802)是一种具有口服活性的LSD1/HDAC6/HDAC8抑制剂,IC50分别为50 nM、11 nM和98 nM,对MAOs具有较好的选择性。JBI-802对AML、CLL、SCLC等多种细胞系具有抗增殖活性，能够抑制肿瘤生长。

LSD1/HDAC6-IN-1 is an orally active compound that functions as a dual inhibitor, targeting lysine specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6). This compound demonstrates promising anti-tumor activity and is particularly valuable for research focused on multiple myeloma (MM) [1].

LSD1/HDAC-IN-1（compound 2）作为一种针对HDAC和LSD1的有效抑制剂，展示出对HDAC1、HDAC2、HDAC6、HDAC8及LSD1的强效抑制作用，其IC50值分别为0.125 nM、0.373 nM、0.0118 nM、0.103 nM和0.571 μM。该化合物在癌症研究领域发挥着关键作用。

HDAC6-IN-3 (Compound 14) is a potent anti-prostate cancer agent that acts as an orally active inhibitor of HDAC6. It has IC50 values ranging from 0.02-1.54 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10. Additionally, HDAC6-IN-3 also demonstrates effective inhibition of MAO-A (IC50 = 0.79 μM) and LSD1 [1].